Vitamin D supplementation for the treatment of COVID-19: Summary of a living Cochrane review.
Vitamin D supplementation for the treatment of COVID-19: Summary of a living Cochrane review.
复制标题
维生素D补充了Covid-19的治疗：生命Cochrane评论的摘要。
DOI：
10.1016/j.explore.2021.06.004
复制
发表时间：
2021-09
期刊：
影响因子：
--
通讯作者：
Wieland LS
中科院分区：
文献类型：
--
作者：
Wieland LS
在COVID-19大流行期间，几项研究观察到维生素D缺乏症（定义为血液中25（OH）D水平低于20 ng/ml）与严重急性呼吸道综合征冠状病毒-2（SARS-CoV-2）阳性、严重COVID-19疾病（包括ICU入院以及有创和无创通气）和COVID-19死亡率增加的风险之间存在关联。1这些观察性研究可能受到维生素D缺乏症风险因素和严重COVID-19疾病风险因素（如年龄和某些基础疾病）重叠的混淆。然而，观察到的相关性表明，维生素D补充剂，特别是维生素D缺乏症患者，可能在预防或治疗COVID-19方面发挥作用。2自2019冠状病毒病大流行开始以来，科克伦已对2019冠状病毒病进行了多项系统性综述，包括关于感染控制和预防以及重症护理的特殊证据收集。科克伦对维生素D治疗COVID-19的效果进行了综述，以发现、批判性评价和总结维生素D作为COVID-19治疗的最新随机试验证据。3本摘要介绍审查结果。科克伦综述的作者根据参与者COVID-19疾病的严重程度将维生素D的随机对照试验分为两组，这是由世界卫生组织开发的临床进展量表定义的。4第一组是在确诊COVID-19（例如，感染SARS-CoV-2）和无症状或轻度疾病的参与者中进行的试验。对于该组，关注的结局包括全因死亡率、中度至重度COVID-19的发展、入院、住院时间、生活质量、维生素D血清水平和不良事件。第二组是在确诊COVID-19并因中度或重度疾病住院的参与者中进行的试验。对于该组，关注的结局包括全因死亡率、临床状态、透析需求、生活质量、病毒清除率、维生素D血清水平和不良事件。作者还计划按基线参与者维生素D状态和维生素D剂量、给药和制剂进行亚组分析。综述作者发现了一项在无症状或轻度COVID-19参与者中进行的维生素D试验。5安慰剂对照试验在印度进行，参与者（n= 40）基线时血清维生素D水平20 ng/mL。随机分配到维生素D组的参与者每天接受60，000 IU的胆钙化醇，持续7天，然后每天补充一次，然后每周补充一次，这取决于达到的维生素D血清水平。试验者报告说，接受维生素D治疗的参与者血清维生素D水平升高，而接受安慰剂治疗的参与者则没有。但是，未报告审查关注的其他结局。基于这一小型试验的信息，综述作者无法就维生素D作为无症状或轻度COVID-19治疗的潜在益处或危害得出结论。
During the COVID-19 pandemic, several studies have observed an association between vitamin D deficiency, defined as blood levels of 25 (OH) D below 20 ng/ml, and increased risk of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) positivity, severe COVID-19 disease (including ICU admission and both invasive and non-invasive ventilation), and COVID-19 mortality. 1 These observational studies are likely confounded by the presence of overlapping risk factors for vitamin D deficiency and risk factors for severe COVID-19 disease, such as age and certain underlying medical conditions. However, the observed associations have suggested that vitamin D supplementation, particularly in people with vitamin D deficiency, may have a role in preventing or treating COVID-19. 2 Since the beginning of the COVID-19 pandemic, Cochrane has produced several systematic reviews on COVID-19, including special collections of evidence on infection control and prevention and on critical care. A Cochrane review on the effects of vitamin D in the treatment of COVID-19 has now been conducted in order to find, critically appraise, and summarize the most recent randomized trial evidence on vitamin D as a treatment for COVID-19. 3 This summary presents the results of that review. The authors of the Cochrane review classified the randomized controlled trials on vitamin D into two groups based on the severity of participant COVID-19 disease, as defined by a clinical progression scale developed by the World Health Organization. 4 The first group was trials conducted in participants with a confirmed diagnosis ofCOVID-19 (eg, infection with SARS-CoV-2) and asymptomatic or mild disease. For this group, the outcomes of interest included allcause mortality, development of moderate to severe COVID-19, admission to hospital, duration of hospitalization, quality of life, vitamin D serum levels, and adverse events. The second group was trials conducted in participants with a confirmed diagnosis of COVID-19 and hospitalized with moderate or severe disease. For this group, the outcomes of interest included all-cause mortality, clinical status, need for dialysis, quality of life, viral clearance, vitamin D serum levels, and adverse events. The authors also planned to carry out subgroup analyses by baseline participant vitamin D status and vitamin D dose, administration, and formulation. The review authors found one trial of vitamin D conducted in participants with asymptomatic or mild COVID-19. 5 The placebo-controlled trial was conducted in India in participants (n= 40) with serum levels of vitamin D 20 ng/mL at baseline. The participants randomized to vitamin D received 60,000 IU of cholecalciferol daily for seven days followed by additional daily and then weekly supplementation, depending on the vitamin D serum levels achieved. The trialists reported that serum vitamin D levels increased in participants treated with vitamin D and not in participants treated with placebo. However, none of the other outcomes of interest for the review were reported. Based on the information from this single small trial, the review authors were unable to reach conclusions on the potential benefits or harms of vitamin D as a treatment for asymptomatic or mild COVID-19.
DOI：
10.1016/j.jsbmb.2020.105751
发表时间：
2020-10-01
影响因子：
4.1
作者：
Entrenas Castillo, Marta;Entrenas Costa, Luis Manuel;Quesada Gomez, Jose Manuel
通讯作者：
Quesada Gomez, Jose Manuel
影响因子：
120.7
作者：
Murai, Igor H.;Fernandes, Alan L.;Pereira, Rosa M. R.
通讯作者：
Pereira, Rosa M. R.
DOI：
10.1016/j.metabol.2021.154753
发表时间：
2021-06
期刊：
Metabolism: clinical and experimental
影响因子：
--
作者：
Bassatne A;Basbous M;Chakhtoura M;El Zein O;Rahme M;El-Hajj Fuleihan G
通讯作者：
El-Hajj Fuleihan G